Day Two - 4 November, 2016 (Friday) |
| Time |
Topics & Speakers |
| 08:30 - 09:00 |
Registration |
Session IV: Phase 1 and Bioavailability/Bioequivalence Trials
Chair: Dr. Tommy Cheung, Deputy Medical Director (Clinical Pharmacology), Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China
Chair: Professor Brian Tomlinson, Adjunct Professor, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, HKSAR, China |
| 09:00 - 09:30 |
Statistical Methods for Phase I Clinical Trial Design
Professor Guosheng Yin, Department of Statistics, The University of Hong Kong, HKSAR, China |
| 09:30 - 10:00 |
The Important Role of Virtual Chinese Population for PK Prediction
Professor Pei Hu, Director, Phase I Unit, Clinical Pharmacology Research Centre, Peking Union Medical College, Beijing, China |
| 10:00 - 10:30 |
Risk Management in Early Clinical Trials
Dr. John Lambert, Vice President, Chief Medical Officer and Global Head Early Phase Medical Sciences, PAREXEL International, UK |
| 10:30 - 11:00 |
Coffee Break |
Session V: Early Phase Clinical Trials in Liver Diseases
Chair: Dr. Thomas Yau, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China
Chair: Professor Man-Fung Yuen, Chair of Gastroenterology and Hepatology, Department of Medicine, The University of Hong Kong, HKSAR, China |
| 11:00 - 11:30 |
Immunotherapy in Hepatocellular Carcinoma
Dr. Tim F. Greten, Head, Gastrointestinal Malignancy Section, Center for Cancer Research, National Cancer Institute, USA |
| 11:30 - 12:00 |
Designing Trials for HCC Patients with Underlying Liver Disease
Dr. Su-Pin Choo, Senior Consultant, Division of Medical Oncology, National Cancer Centre Singapore, Singapore |
| 12:00 - 12:30 |
Drug Development of HCC: Where are We Now in Asia
Dr. Thomas Yau, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China |
| 12:30 - 14:00 |
Lunch |
Session VI: Neuroscience and Immunology Research
Chair: Professor S.L. Ho, Professor, Department of Medicine, The University of Hong Kong, HKSAR, China
Chair: Dr. Koon-Ho Chan, Clinical Associate Professor, Department of Medicine, The University of Hong Kong, HKSAR, China |
| 14:00 - 14:30 |
Development of New Therapeutics for Rheumatoid Arthritis
Dr. Tommy Cheung, Deputy Medical Director (Clinical Pharmacology), Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China |
| 14:30 - 15:00 |
Challenge and opportunity of drug development for neuroprotective in Parkinson’s disease
Professor Piu Chan, Professor in Neurology and Director of Beijing Institute of Geriatrics and Gerontology, Xuanwu Hospital of Capital Medical University, Beijing, China |
| 15:00 - 15:30 |
Targeting Purines as Neuroprotective Therapy for Parkinson’s Disease
Professor Michael Schwarzschild, Professor of Neurology, Harvard Medical School, Mass General Institute for Neurodegenerative Disease/Neurology, Massachusetts General Hospital, Boston, USA |
| 15:30 - 16:00 |
Novel Approaches to the Pharmacological Treatment of Parkinson’s Disease
Professor Peter Jenner, Emeritus Professor, King’s College London, London, UK |
| 16:00 - 16:30 |
Coffee Break |
Session VII: Innovation in Oncology Treatment
Chair: Dr. Victor Lee, Clinical Assistant Professor, Department of Clinical Oncology, The University of Hong Kong, HKSAR, China
Chair: Dr. Stephen L. Chan, Associate (Clinical) Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, HKSAR, China |
| 16:30 - 17:00 |
Intracrine Signaling of VEGF in Colorectal Cancer
Professor Lee M. Ellis, Professor of Surgery, and Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, USA |
| 17:00 - 17:30 |
Targeting Genomic Instability and Aneuploidy in Cancer: Is it Possible
Professor Tak-wah Mak, Director, the Campbell Family for Breast Cancer Researh at Princess Margaret Cancel Centre, University Health Network / University Professor, Department of Medicine, Medical Biophysics and Immunology, University of Toronto, Toronto, Canada |
| 17:30 - 18:00 |
Recent Advances in the Management of Pancreatic Cancer
Professor Andrew Ko, Professor, Department of Medicine (Hematology/Oncology), University of California San Francisco, USA |
| 18:00 - 18:15 |
Summary and Closing Remarks
Professor Bernard Cheung, Medical Director, Phase 1 Clinical Trials Centre, The University of Hong Kong, HKSAR, China |
